Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Evolocumab - Amgen

Next Previous
Drug Profile

Evolocumab - Amgen

Alternative Names: AMG-145; Repatha

Latest Information Update: 02 Feb 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Amgen
  • Developer Amgen; Amgen Astellas BioPharma; University Hospital Inselspital
  • Class Anti-ischaemics; Antihyperlipidaemics; Monoclonal antibodies; Vascular disorder therapies
  • Mechanism of Action PCSK9 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Hypercholesterolaemia
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Coronary disorders; Hypercholesterolaemia; Hyperlipoproteinaemia type IIa; Myocardial infarction; Stroke
  • Phase III Coronary artery disease; Dyslipidaemias; Hyperlipidaemia

Most Recent Events

  • 02 Feb 2026 Evolocumab is still in phase III development in Coronary disorders in USA, Canada, Netherlands, Hungary, Germany, Spain, Argentina, Australia, Austria, Belgium, Brazil, Bulgaria, Czech Republic, Denmark, Estonia, Finland, France, Greece, Iceland, Italy, South Korea, Latvia, Lithuania, Mexico, Poland, Portugal, Romania, Russia, Slovakia, Sweden, Taiwan, Ukraine, United Kingdom (SC) (NCT03872401) (CTIS2018-004565-14)
  • 02 Feb 2026 No development reported - Phase-III for Hyperlipoproteinaemia type IIa (Adjunctive treatment, In adolescents, In children) in Austria (SC)
  • 02 Feb 2026 No development reported - Phase-III for Hyperlipoproteinaemia type IIa (Adjunctive treatment, In adolescents, In children) in Brazil (SC)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top